ABSTRACT. This report deals with three additional canine cases of sterile panniculitis treated by oral administration of tacrolimus and prednisolone. The oral tacrolimus treatment was proved to be an affordable medical protocol for canine sterile panniculitis with good efficacy and without adverse effects.
Canine sterile panniculitis is defined as the inflammation of subcutaneous fat tissue without a microbial infection but its pathogenesis is not well understood [4, 6] . Panniculitis in dogs with multiple lesions is mainly controlled with systemic prednisolone. However, some intractable cases respond inadequately to treatment with glucocorticoids, which could not be tapered off. In a previous paper, we reported a canine case (case 1 of this reprt) of sterile panniculitis successfully treated with a combination of prednisolone and tacrolimus (Prograf, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan) [1] . Therefore, we conjectured that this combination of drugs was most effective for control of this disease. This paper deals with three additional cases of sterile panniculitis treated by oral administration of prednisolone and tacrolimus. The addition of a low dosage of tacrolimus successfully reduced the dosage of prednisolone.
Three dogs with spontaneous sterile panniculitis admitted to the Nihon University Animal Medical Center, Kanagawa, Japan, were included in the study (Table 1) . These cases were diagnosed by clinical features histopathological analysis of biopsy specimens from skin lesions, and bacteriological examination [4] . Histopathology of the skin biopsy specimens from these cases revealed pyogranulomatous inflammation of adipose tissue with no microorganisms in neutrophils and macrophages. Cultural examination of biopsy specimens from the cases were also negative.
A physical examination, complete blood cell count, and serum biochemical analysis were performed on each patient prior to enrolment into the trial. The nodules ruptured and discharged oily and bloody fluids in cases 1 and 4, which both had slight fevers and leucocytosis.
The medical history of cases 1 and 4 revealed that they had been administered prednisolone orally at a dosage of 1 mg/kg once a day. In these cases, however, nodules relapsed and ruptured with discharge of oily bloody fluids when the dosage of prednisolone was reduced to 0.5 mg/kg once a day. After this tacrolimus at a dosage of 0.03 mg/kg and prednisone (1 mg/kg) were given orally once a day. After 2 weeks, tacrolimus was continued and prednisolone was reduced to 0.5 mg / kg orally in these 2 cases, which had improved clinical signs. These cases were later treated with tacrolimus orally once a day (0.03 mg/kg) and predonisone every other day (0.5 mg/kg).
Case 2 had nodules with no other clinical signs. Case 3 had a slight fever and non-ruptured nodules. For cases 2 and 3, tacrolimus at a dosage of 0.03 mg/kg and prednisone (1 mg/kg) were given orally once a day. After 2 weeks, tacrolimus was continued and prednisolone was reduced to 0.5 mg / kg orally in these 2 cases, which had improved clinical signs. Prednisolone and tacrolimus were discontinued for case 2 after 4 weeks and case 3 after 3 weeks, and skin lesions of these 2 cases were not detected for 6 months after the drugs were discontinued.
During administration of tacrolimus, complete blood cell counts and the results of serum biochemical analyses returned to within the normal range. No relapse of panniculitis was detected in these cases and no adverse effects of the drugs were observed ( Table 2) .
Cases of panniculitis with multiple lesions treated with glucocorticoids, vitamin E, and cyclosporin A has been reported [4, 7] . However, these drugs could not be contin- ued for long-term because of adverse effects in intractable and inadequately responding cases. In all cases in this study, tacrolimus successfully subsuided the inflammation of paniculitis in combination with prednisolone, and then the dosage of prednisolone was reduced or discontinued, depending on the clinical state. Although tacrolimus and cyclosporin A share similar physicochemical properities and a common mechanism of action, their pharmacokinetics are different and unpredictable [2] . Tacrolimus was demonstrated to inhibit interleukin 2 (IL-2) production, the expression of IL-2 receptors, and cytotoxic T-cell generation at about a 100-fold lower concentration than that of cyclosporin A [3] . There is some evidence that tacrolimus has hepatotoxicity and nephrotoxicity. These side effects of tacrolimus are induced at a dosage above 0.4 mg/kg/day in dogs [5, 6] . This dosage was used to produce an immunosuppressive condition for organ transplantation dogs. Tacrolimus is clinically given at a dosage that has a 50-fold lower concentration than cyclosporin A due to the pharmacokinetic differences between the two drugs [2] . In all the cases in this study, we used a low dosage (0.03 mg/kg/day) to produce an anti-inflammation condition. This low dosage was useful for treatment of sterile panniculitis in dogs. 
